



**SDI Review Form 1.6**

Journal Name:	<a href="#">International Journal of Medical and Pharmaceutical Case Reports</a>
Manuscript Number:	Ms_IJMPCR_50770
Title of the Manuscript:	CASE SERIES: CORRECTING DEFORMITIES: ELIMINATING THE FEAR OF STIGMA
Type of the Article	Case report

**General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)

**PART 1: Review Comments**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments	<ol style="list-style-type: none"> <li>1. Anti microbial resistance in leprosy due therapy of monthly once Rifamycin, clofazamine and daily once dapsone.</li> <li>2. Report of Global consultation by WHO recommended Implementing new WHO guideline; As determined by the Expert Committee in 2010 the recommended regimen for treatment of rifampicin resistant cases consists of <u>three drugs daily for six months (clofazimine, minocycline and ofloxacin or clarithromycin) and two drugs daily for 18 months (clofazimine plus ofloxacin or minocycline)</u>.</li> <li>3. In 2016 WHO with NEPAL as collaboration centre done a study through out the world and published in google as AMR in leprosy.</li> <li>4. By following the above regime downgrading of leprosy to type1 and type2 reactions and further complications can be prevented and complete cure can be attained.</li> <li>5. <u>By giving daily regime rifamycin, resistance in TB ATT therapy also can be prevented.</u></li> <li>6. Following the above daily dose of MDT we save the world from MDR in Leprosy , ATT and complications. Further study to be done.</li> </ol>	
<b>Minor</b> REVISION comments		
<b>Optional/General</b> comments		

**PART 2:**

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Are there ethical issues in this manuscript?</b>	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

**Reviewer Details:**

Name:	<b>D. Ramachandrareddy</b>
Department, University & Country	<b>Vinayaka Mission Research and Deemed University, India</b>